Lynn Cahill Hoy, NP
Adult Health · Camillus, NYNPI 1811976160
Payments from drug & device makers
Across 62 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$233
- Mannkind Corporation$108
- Abbott$99
- Lilly USA, LLC$98
- Exact Sciences$67
- Insulet Corporation$60
- plus $512 from 23 others
What the payments were for
- Food & beverage$1,13496%
- Education$434%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $233 |
| Mannkind Corporation | 4 | $108 |
| Abbott | 3 | $99 |
| Lilly USA, LLC | 6 | $98 |
| Exact Sciences | 4 | $67 |
| Insulet Corporation | 3 | $60 |
| Boehringer Ingelheim | 3 | $55 |
| Sanofi-aventis U.S. LLC | 2 | $50 |
| Bayer | 2 | $49 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| AstraZeneca | 2 | $31 |
| Shield Therapeutics Inc | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Amgen | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Merck | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| AbbVie | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,176 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 255 | $299,703 |
| MounjaroTirzepatide | 108 | $153,988 |
| Tresiba Flextouch U-200Insulin Degludec | 86 | $84,510 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $64,322 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 58 | $51,641 |
| Tresiba Flextouch U-100Insulin Degludec | 90 | $50,847 |
| TrulicityDulaglutide | 50 | $48,559 |
| JardianceEmpagliflozin | 44 | $45,935 |
| Novolog FlexpenInsulin Aspart | 123 | $34,207 |
| InvokanaCanagliflozin | 24 | $13,665 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 137 | $13,284 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $13,007 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $12,452 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $12,365 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $12,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $233 | $304,057268 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $98 | $205,654169 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $55 | $97,576102 claims |
| MerckJanumet Xr | $17 | $7,06413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.
Other adult health in Camillus
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.